Sirnaomics Inc, a United States-based biopharmaceutical company, has completed the dose administration for the first patient in a Phase 2a clinical study of the company's lead drug candidate, STP705, intended to treat cutaneous basal cell carcinoma, it was reported on Sunday.

The open label, dose escalation study is intended to assess the efficacy and safety of intralesional injection of the product in adult patients with cutaneous basal cell carcinoma confirmed with biopsy samples. The aim is to determine the STP705's safe and effective recommended dose for the treatment of basal cell carcinoma and analysis of biomarkers common to basal cell carcinoma formation pathway including TGF-Beta1 and COX-2. The trial includes three dose escalation cohorts ranging from 30 micrograms to 90 micrograms with five patients in each group.

The primary endpoint of this trial is to assess patients for complete histological clearance of the tumour cells within the treated basal cell carcinoma lesion with secondary endpoints, evaluating patients for investigational product treatment related adverse events, as well as serious adverse events, and cutaneous skin reactions.

The firm is likely to reveal initial clinical data from the trial in 2021.